Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


The increase in obesity and the aging of the population has lead to an increase in the incidence of type 2 diabetes. This has led to the development of new drugs such as thiazolidinediones (TZDs) which are Peroxisome Proliferator-Activated Receptor (PPAR-gamma) agonists, to treat type 2 diabetes. TZDs have recently been at the center of a controversy with regards to their cardiovascular safety. Pioglitazone is a TZD which has been shown to be effective in glycemic control by lowering insulin resistance. Pioglitazone also has beneficial effects on lipid metabolism and cardiovascular risk. The safety and efficacy of pioglitazone including its pleotropic effects are discussed at length in this article.

Original languageEnglish (US)
JournalClinical Medicine Insights: Endocrinology and Diabetes
StatePublished - Jan 2010


  • Pioglitazone
  • cardiovascular
  • diabetes
  • efficacy
  • safety

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review'. Together they form a unique fingerprint.

Cite this